Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
June 11 2024 - 6:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 10 June 2024, London UK
Statement: Zantac (ranitidine) litigation - GSK starts process for
appeal of recent Delaware Daubert decision
● Delaware Superior Court's ruling inconsistent with
how Daubert standard* has previously been applied in Delaware and
federal courts
● Application has been filed seeking right of appeal
to the Delaware Supreme Court
● GSK, Pfizer, Sanofi, and Boehringer Ingelheim are
all parties to the application
●
Scientific consensus
remains that there is no consistent or reliable evidence that
ranitidine increases the risk of any cancer
GSK plc (LSE/NYSE: GSK) today confirms that the Company has taken
the first step to seek appeal of the recent Daubert ruling, made by
the Delaware Superior Court, which permits plaintiff expert
testimony as part of the Zantac (ranitidine) litigation in
Delaware. GSK strongly disagrees with the Delaware Superior Court's
ruling and has filed an application with the court to appeal to the
Delaware Supreme Court for interlocutory review of the decision.
Pfizer, Sanofi, and Boehringer Ingelheim are all parties to the
application.
While interlocutory reviews are granted in exceptional
circumstances, GSK believes such circumstances are present here and
that it is important to raise these matters now to the Delaware
Supreme Court.
The Superior Court's ruling is inconsistent with how the Daubert
standard has been applied previously in Delaware and federal
courts. As such, differing rulings interpreting how the Daubert
standard is to be applied to litigation before Delaware Courts, now
exist. The Superior Court's ruling would therefore have profound
implications for all companies and businesses incorporated in
Delaware.
If the Delaware Superior Court grants the application for appeal,
the case for interlocutory review of the decision will proceed to
the Delaware Supreme Court for consideration.
If the Delaware Superior Court rejects the application, GSK and the
other defendants will seek leave to appeal directly to the Delaware
Supreme Court.
A decision, on whether to grant interlocutory review and hear the
appeal, would be expected from the Delaware Supreme Court sometime
later this year.
The scientific consensus remains that there is no consistent or
reliable evidence that ranitidine increases the risk of any cancer.
There are 16 epidemiological studies looking at human data
regarding the use of ranitidine, including outcomes for more than 1
million patients using ranitidine, supporting this
consensus.
GSK remains committed to vigorously defending itself and managing
this litigation in the best interests of the Company and its
shareholders.
Notes to Editors
* Also known as the "Daubert Test," the Daubert standard is a
method used by US courts to determine whether or not expert
testimony should be admissible at trial. This standard applies to
both civil and criminal cases and can be raised by either the
defendant or plaintiff. The standard came about because Federal
Rule of Evidence 702 requires that expert testimony consists of
scientific, technical or other specialised knowledge that
legitimately helps the judge or jury understand the evidence or
issues that have been raised in the case. A Daubert ruling, issued
by the court, determines whether or not the testimony is
admissible.
The term "Daubert Standard" comes from the United States Supreme
Court case: Daubert v Merrell Dow
Pharmaceuticals Inc 509 US
579 (1993)
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
GSK enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q1 Results for 2024.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: June
11, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From May 2024 to Jun 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jun 2023 to Jun 2024